Roche: presentation of 40 hematology abstracts
(CercleFinance.com) - Roche announces the presentation of more than 40 abstracts on nine blood disorders at the American Society of Hematology (ASH) 2024 meeting.
Data include results on lymphoma treatments, with long-term follow-ups for Polivy (polatuzumab vedotin), Lunsumio (mosunetuzumab) and Columvi (glofitamab), as well as new data on investigative combinations.
Highlights include a five-year study showing a positive effect of Polivy in first-line diffuse large B-cell lymphoma.
In addition, extended data on Lunsumio and Columvi show durable remissions and immune recovery, reinforcing their use for follicular lymphoma and DLBCL in third-line and more.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Data include results on lymphoma treatments, with long-term follow-ups for Polivy (polatuzumab vedotin), Lunsumio (mosunetuzumab) and Columvi (glofitamab), as well as new data on investigative combinations.
Highlights include a five-year study showing a positive effect of Polivy in first-line diffuse large B-cell lymphoma.
In addition, extended data on Lunsumio and Columvi show durable remissions and immune recovery, reinforcing their use for follicular lymphoma and DLBCL in third-line and more.
Copyright (c) 2024 CercleFinance.com. All rights reserved.